Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects

Monoclonal antibody therapy using CD38 as a target remains central to managing human multiple myeloma (MM). CD38 was selected early on as a target for mAb-mediated therapy for MM, driven by findings from an early Cluster of Differentiation (CD) Workshop. The first CD38-targeting antibody to be appro...

Full description

Saved in:
Bibliographic Details
Main Authors: Alberto L. Horenstein, Angelo C. Faini, Fabio Morandi, Erika Ortolan, Paola Storti, Nicola Giuliani, Paul G. Richardson, Fabio Malavasi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
antibody therapies
CD38 monoclonal antibodies
IgG Fc receptors
ectoenzymatic activity
multiple myeloma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1519300/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items